美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Definium Therapeutics

36.82

-3.4300-8.52%

盤前：37.300.4800+1.30%08:42 EDT

成交量：452.69萬

成交額：1.70億

市值：49.47億

市盈率：-10.57

高：40.45

開：40.45

低：36.78

收：40.25

52周最高：49.70

52周最低：8.77

股本：1.34億

流通股本：1.30億

量比：1.71

換手率：3.49%

股息：- -

股息率：- -

每股收益(TTM):-3.4823

每股收益(LYR):-2.0600

淨資產收益率：-64.09%

總資產收益率：-20.64%

市淨率：5.39

市盈率(LYR):-17.87

資料載入中...

總覽公司新聞資訊公告

Definium公司基於LSD的藥片在晚期臨床試驗中減輕了抑鬱症狀

Definium Therapeutics公布DT120口崩片治療重度抑鬱症的3期EMERGE研究積極頂線結果

Definium Therapeutics：DT120口崩片研究達成主要及所有關鍵次要療效終點

Definium Therapeutics 公布 DT120 ODT 臨床數據：總體耐受性良好，未出現嚴重不良事件或自殺傾向信號

Definium Therapeutics將於2026年6月22日討論重度抑鬱症III期EMERGE研究的頂線結果

Definium Therapeutics宣佈在DT120 Odt針對重度抑鬱症的第二個三期關鍵研究「Ascend」中完成首例患者給藥

異動解讀 | 特朗普簽署迷幻藥監管支持行政命令，Definium Therapeutics盤前大漲6.34%

異動解讀 | 特朗普簽署迷幻藥監管支持行政命令，Definium Therapeutics夜盤大漲5.65%

BUZZ--美國股票走勢-TopBuild, MDA Space, Biogen

Definium Therapeutics飆升14.5%，COMPASS Pathways暴漲21.5%，GH Research躍升18.9%，Enveric Biosciences上漲6.6%，Cybin美國上市股票勁揚15.5%

BUZZ-特朗普發出監管支持信號後，迷幻藥開發商崛起

Definium Therapeutics 研發DT120口腔崩解片針對廣泛性焦慮症、重度抑鬱症及其他嚴重腦健康疾病

美國研究綜述-雪佛龍、Littelfuse、派克-漢尼汾

美國研究綜述-雪佛龍、Littelfuse、派克-漢尼汾

Piper Sandler 首予 Definium Therapeutics 增持評級，目標價49美元

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/DFTX/news?page=3"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"DFTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DFTX\",,,,,undefined,":{"symbol":"DFTX","market":"US","secType":"STK","nameCN":"Definium Therapeutics","latestPrice":36.82,"timestamp":1789502400000,"preClose":40.25,"halted":0,"volume":4526876,"hourTrading":{"tag":"盘前","latestPrice":37.3,"preClose":36.82,"latestTime":"08:42 EDT","volume":1320,"amount":49220.371199999994,"timestamp":1789562579632,"change":0.48,"changeRate":0.013036,"amplitude":0.01032},"delay":0,"changeRate":-0.08521739130434781,"floatShares":129766311,"shares":134366950,"eps":-3.482311,"marketStatus":"盤前交易","change":-3.43,"latestTime":"09-16 08:59:54 EDT","open":40.445,"high":40.445,"low":36.775,"amount":169838718.11286402,"amplitude":0.09118,"askPrice":37.37,"askSize":40,"bidPrice":36.86,"bidSize":14,"shortable":3,"etf":0,"ttmEps":-3.482311,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789565400000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":36.82,"preHourTrading":{"tag":"盘前","latestPrice":37.3,"preClose":36.82,"latestTime":"08:42 EDT","volume":1320,"amount":49220.371199999994,"timestamp":1789562579632,"change":0.48,"changeRate":0.013036,"amplitude":0.01032},"postHourTrading":{"tag":"盘后","latestPrice":37.18,"preClose":36.82,"latestTime":"19:58 EDT","volume":48449,"amount":1786475.1135,"timestamp":1789516731320,"change":0.36,"changeRate":0.009777,"amplitude":0.01711},"volumeRatio":1.711397079972522,"impliedVol":0.6873,"impliedVolPercentile":0.0301},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DFTX\",,,,,undefined,":{"symbol":"DFTX","floatShares":129766311,"roa":"-20.64%","roe":"-64.09%","lyrEps":-2.059999,"volumeRatio":1.711397079972522,"shares":134366950,"dividePrice":0,"high":40.445,"amplitude":0.09118,"preClose":40.25,"low":36.775,"week52Low":8.7732,"pbRate":"5.39","week52High":49.7,"institutionHeld":0,"latestPrice":36.82,"committee":-0.481481,"eps":-3.482311,"divideRate":0,"volume":4526876,"delay":0,"ttmEps":-3.482311,"open":40.445,"prevYearClose":13.39,"prevWeekClose":38.89,"prevMonthClose":39.72,"prevQuarterClose":47.04,"fiveDayClose":38.23,"twentyDayClose":45.26,"sixtyDayClose":24.48},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DFTX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-06","symbol":"DFTX","fiscalQuarterEnding":"2026/06","expectedEps":-0.55,"name":null,"time":"盤後","type":"earning","dateTimestamp":1785988800000,"reportTimeType":"post","actualEps":-1.44},{"market":"US","date":"2026-05-07","symbol":"DFTX","fiscalQuarterEnding":"2026/03","expectedEps":-0.47,"name":null,"time":"盤後","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"post","actualEps":-0.71},{"market":"US","date":"2026-02-26","symbol":"DFTX","fiscalQuarterEnding":"2025/12","expectedEps":-0.45,"name":null,"time":"盤後","type":"earning","dateTimestamp":1772082000000,"reportTimeType":"post","actualEps":-0.45}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DFTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"DFTX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3889,"buy":0.6111,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6111,"analysts":18,"updateTime":1787025600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/DFTX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"DFTX","date":"2026-09-15","current":-10.573438,"percent":0.290909,"low":-27.074722,"twenty":-17.242844,"median":-11.217373,"eighty":-9.903787,"high":-8.802064,"avg":-13.946144,"sd":5.371025,"marketCap":5408269737},"quantilePoints":[{"date":"2026-01-16","current":-9.013032,"twenty":-8.970838,"median":-8.907548,"eighty":-8.844258,"marketCap":1515072711},{"date":"2026-01-23","current":-9.944809,"twenty":-9.944809,"median":-9.423248,"eighty":-8.819645,"marketCap":1671702464},{"date":"2026-01-30","current":-10.103035,"twenty":-10.103035,"median":-9.868626,"eighty":-9.013032,"marketCap":1698299969},{"date":"2026-02-06","current":-9.522872,"twenty":-10.196799,"median":-9.918438,"eighty":-9.522872,"marketCap":1600775783},{"date":"2026-02-13","current":-9.511152,"twenty":-10.179218,"median":-9.944809,"eighty":-9.522872,"marketCap":1598805598},{"date":"2026-02-20","current":-10.120616,"twenty":-10.18039,"median":-9.944809,"eighty":-9.520528,"marketCap":1701255248},{"date":"2026-02-27","current":-9.267085,"twenty":-10.187422,"median":-9.96239,"eighty":-9.520528,"marketCap":1703225433},{"date":"2026-03-06","current":-9.519961,"twenty":-10.18039,"median":-9.903787,"eighty":-9.502065,"marketCap":1749702163},{"date":"2026-03-13","current":-9.753213,"twenty":-10.18039,"median":-9.918437,"eighty":-9.518199,"marketCap":1792572359},{"date":"2026-03-20","current":-10.122078,"twenty":-10.169841,"median":-9.903787,"eighty":-9.52229,"marketCap":1860367087},{"date":"2026-03-27","current":-10.273963,"twenty":-10.169841,"median":-9.918437,"eighty":-9.559599,"marketCap":1888282563},{"date":"2026-04-02","current":-11.174427,"twenty":-10.181562,"median":-9.918437,"eighty":-9.550417,"marketCap":2053781457},{"date":"2026-04-10","current":-11.619234,"twenty":-10.247114,"median":-9.944809,"eighty":-9.57529,"marketCap":2135533923},{"date":"2026-04-17","current":-12.18338,"twenty":-10.396104,"median":-9.980506,"eighty":-9.589394,"marketCap":2239219977},{"date":"2026-04-24","current":-12.617338,"twenty":-11.167918,"median":-10.038572,"eighty":-9.618687,"marketCap":2318978480},{"date":"2026-05-01","current":-11.86876,"twenty":-11.389236,"median":-10.10442,"eighty":-9.643639,"marketCap":2181395062},{"date":"2026-05-08","current":-13.767387,"twenty":-11.71579,"median":-10.122078,"eighty":-9.665202,"marketCap":2530349365},{"date":"2026-05-15","current":-9.802755,"twenty":-11.643102,"median":-10.113211,"eighty":-9.689477,"marketCap":2328575817},{"date":"2026-05-22","current":-10.399644,"twenty":-11.570414,"median":-10.105791,"eighty":-9.636028,"marketCap":2470362634},{"date":"2026-05-29","current":-10.780735,"twenty":-11.483622,"median":-10.120616,"eighty":-9.642537,"marketCap":2560888064},{"date":"2026-06-05","current":-11.290386,"twenty":-11.393576,"median":-10.145827,"eighty":-9.660184,"marketCap":2681952193},{"date":"2026-06-12","current":-11.069996,"twenty":-11.344489,"median":-10.179218,"eighty":-9.68473,"marketCap":2629600138},{"date":"2026-06-18","current":-11.216923,"twenty":-11.349156,"median":-10.196799,"eighty":-9.702279,"marketCap":2664501508},{"date":"2026-06-26","current":-20.565124,"twenty":-11.510745,"median":-10.247973,"eighty":-9.723056,"marketCap":4885101210},{"date":"2026-07-02","current":-24.252692,"twenty":-11.77112,"median":-10.299843,"eighty":-9.753213,"marketCap":5761057223},{"date":"2026-07-10","current":-27.074722,"twenty":-12.069466,"median":-10.333633,"eighty":-9.796609,"marketCap":6431410656},{"date":"2026-07-17","current":-24.643864,"twenty":-12.519698,"median":-10.492938,"eighty":-9.802755,"marketCap":5853977501},{"date":"2026-07-24","current":-23.990048,"twenty":-12.931958,"median":-10.537388,"eighty":-9.812883,"marketCap":5698667894},{"date":"2026-07-31","current":-24.861803,"twenty":-14.440728,"median":-10.67054,"eighty":-9.817222,"marketCap":5905747370},{"date":"2026-08-07","current":-17.312135,"twenty":-19.588062,"median":-10.789918,"eighty":-9.824231,"marketCap":6124773739},{"date":"2026-08-14","current":-16.673146,"twenty":-17.887875,"median":-10.831241,"eighty":-9.831914,"marketCap":5898709105},{"date":"2026-08-21","current":-17.242844,"twenty":-17.526933,"median":-11.058518,"eighty":-9.861594,"marketCap":6100259530},{"date":"2026-08-28","current":-16.642763,"twenty":-17.426666,"median":-11.092954,"eighty":-9.887379,"marketCap":5887959749},{"date":"2026-09-04","current":-14.432336,"twenty":-17.33018,"median":-11.139168,"eighty":-9.901443,"marketCap":5105944100},{"date":"2026-09-11","current":-14.329791,"twenty":-17.27056,"median":-11.195675,"eighty":-9.903787,"marketCap":5069665023},{"date":"2026-09-15","current":-15.286883,"twenty":-17.242844,"median":-11.217373,"eighty":-9.903787,"marketCap":5408269737}],"updateTime":1789562607130},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DFTX\",pageSize:20,pageCount:3,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2645029980","title":"Definium公司基於LSD的藥片在晚期臨床試驗中減輕了抑鬱症狀","url":"https://stock-news.laohu8.com/highlight/detail?id=2645029980","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645029980?lang=zh_tw&edition=fundamental","pubTime":"2026-06-22 19:00","pubTimestamp":1782126036,"startTime":"0","endTime":"0","summary":"路透6月22日 - Definium Therapeutics公司周一表示，在一项晚期临床试验中，其基于LSD的试验性药片单次给药显著减轻了患者的重度抑郁症状。Definium公司的药物总体耐受性良好，99%的不良事件为轻度至中度，主要发生在给药当天，且未观察到严重的安全问题或自杀念头增加的情况。该公司表示，这些结果使其更接近向美国食品药品监督管理局提交申请，目前正在开展第二项抑郁症晚期临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nL4S42U0R9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109486940","title":"Definium Therapeutics公布DT120口崩片治療重度抑鬱症的3期EMERGE研究積極頂線結果","url":"https://stock-news.laohu8.com/highlight/detail?id=1109486940","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109486940?lang=zh_tw&edition=fundamental","pubTime":"2026-06-22 19:00","pubTimestamp":1782126018,"startTime":"0","endTime":"0","summary":"Definium Therapeutics宣布，其针对重度抑郁症（MDD）的候选药物DT120口崩片（ODT）在关键的3期EMERGE研究中取得了积极的顶线结果。该研究达到了其主要终点，显示出与安慰剂相比，在改善抑郁症状方面具有统计学显著性和临床意义的优势。安全性特征与先前研究一致，未发现新的安全问题。这一积极数据为DT120的后续监管申请奠定了坚实基础，标志着公司在精神疾病治疗领域的重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147229029","title":"Definium Therapeutics：DT120口崩片研究達成主要及所有關鍵次要療效終點","url":"https://stock-news.laohu8.com/highlight/detail?id=1147229029","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147229029?lang=zh_tw&edition=fundamental","pubTime":"2026-06-22 19:00","pubTimestamp":1782126016,"startTime":"0","endTime":"0","summary":"Definium Therapeutics宣布，其候选药物DT120口崩片的一项临床研究，已成功达成预设的主要疗效终点以及所有关键性的次要疗效终点。这一积极结果标志着该药物在目标适应症的开发中取得了重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138440350","title":"Definium Therapeutics 公布 DT120 ODT 臨床數據：總體耐受性良好，未出現嚴重不良事件或自殺傾向信號","url":"https://stock-news.laohu8.com/highlight/detail?id=1138440350","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138440350?lang=zh_tw&edition=fundamental","pubTime":"2026-06-22 19:00","pubTimestamp":1782126014,"startTime":"0","endTime":"0","summary":"Definium Therapeutics (DFTX) 近日公布了其候选药物 DT120 口腔崩解片（ODT）的临床研究结果。数据显示，该药物在试验中总体耐受性良好，未观察到任何严重不良事件，也未发现与自杀倾向相关的信号。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194348262","title":"Definium Therapeutics將於2026年6月22日討論重度抑鬱症III期EMERGE研究的頂線結果","url":"https://stock-news.laohu8.com/highlight/detail?id=1194348262","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194348262?lang=zh_tw&edition=fundamental","pubTime":"2026-06-22 05:01","pubTimestamp":1782075697,"startTime":"0","endTime":"0","summary":"Definium Therapeutics宣布，将于2026年6月22日就其针对重度抑郁症的III期EMERGE研究的顶线结果进行讨论。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137501338","title":"Definium Therapeutics宣佈在DT120 Odt針對重度抑鬱症的第二個三期關鍵研究「Ascend」中完成首例患者給藥","url":"https://stock-news.laohu8.com/highlight/detail?id=1137501338","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137501338?lang=zh_tw&edition=fundamental","pubTime":"2026-05-12 19:01","pubTimestamp":1778583709,"startTime":"0","endTime":"0","summary":"Definium Therapeutics宣布，在其针对重度抑郁症的候选药物DT120 Odt的第二个关键性三期临床试验“Ascend”中，已完成对首例患者的给药。这标志着该药物临床开发项目的一个重要里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142902855","title":"異動解讀 | 特朗普簽署迷幻藥監管支持行政命令，Definium Therapeutics盤前大漲6.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=1142902855","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142902855?lang=zh_tw&edition=fundamental","pubTime":"2026-04-21 17:11","pubTimestamp":1776762674,"startTime":"0","endTime":"0","summary":"Definium Therapeutics（股票代码：DFTX）今日盘前股价大幅上涨6.34%，引起了市场的广泛关注。消息面上，此次股价异动主要源于行业性的政策利好。据报道，美国总统特朗普签署了一项行政命令，要求卫生监管机构加快对伊博格碱等迷幻药的审查流程，并拨出5000万美元专款用于相关研究。此举被市场解读为政府对迷幻药治疗领域的正式认可与实质性支持，从而提振了投资者信心。受此消息影响，整个迷幻药开发板块应声上涨。分析人士指出，该行政命令标志着官方支持从“空谈”转向“真实可操作”，获得“突破性疗法”称号的迷幻药未来有望获得优先审查，从而大幅缩短审批时间，为相关公司带来发展机遇。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127343471","title":"異動解讀 | 特朗普簽署迷幻藥監管支持行政命令，Definium Therapeutics夜盤大漲5.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=1127343471","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127343471?lang=zh_tw&edition=fundamental","pubTime":"2026-04-21 10:06","pubTimestamp":1776737206,"startTime":"0","endTime":"0","summary":"迷幻药开发商Definium Therapeutics今日夜盘股价大幅上涨5.65%，表现亮眼。消息面上，此次股价异动主要源于行业性的政策利好。据报道，美国总统特朗普于周六签署了一项行政命令，要求卫生监管机构加快对伊博格碱等迷幻药的审查流程，并拨出5000万美元专款用于相关研究。此举被市场解读为政府对迷幻药治疗领域的正式认可与实质性支持。受此消息提振，整个迷幻药开发板块应声上涨。除Definium Therapeutics外，Atai Beckley、Compass Pathways、Enveric Biosciences等多家同业公司股价均录得显著涨幅。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628725578","title":"BUZZ--美國股票走勢-TopBuild, MDA Space, Biogen","url":"https://stock-news.laohu8.com/highlight/detail?id=2628725578","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628725578?lang=zh_tw&edition=fundamental","pubTime":"2026-04-20 21:06","pubTimestamp":1776690369,"startTime":"0","endTime":"0","summary":"由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nL4T4130WA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CCL.UK","AMZP","JEF","ASTN","CCL","OKTA","SOC","HLXX","META","DVN","SCCO","OXY","CDE","FCX","AAL","CVX","DFTX","WHR","HL","USAR","BHP.AU","GTLB","RBC","CMPS","MRVL","LION","PASG","SF","CLF","JPMO","CLDX","AU","BIIB","ASTS","AZYY","RIO.AU","GHRS","GLSI","ATAI","NKTR","FRMI","AMZD","NEM","SRFM","RIO.UK","BMI","QXO","XOM","BLD","AMZN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161481278","title":"Definium Therapeutics飆升14.5%，COMPASS Pathways暴漲21.5%，GH Research躍升18.9%，Enveric Biosciences上漲6.6%，Cybin美國上市股票勁揚15.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1161481278","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161481278?lang=zh_tw&edition=fundamental","pubTime":"2026-04-20 18:40","pubTimestamp":1776681631,"startTime":"0","endTime":"0","summary":"生物科技板块今日表现亮眼，多只精神健康领域个股出现大幅上涨。Definium Therapeutics股价强势攀升14.5%，COMPASS Pathways更实现21.5%的惊人涨幅。GH Research同期录得18.9%的可观增长，Enveric Biosciences也上涨6.6%。值得关注的是，Cybin公司的美国上市股票同样表现强劲，单日涨幅达到15.5%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GHRS","ENVB","BK4139","CMPS","ATAI","DFTX","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628454697","title":"BUZZ-特朗普發出監管支持信號後，迷幻藥開發商崛起","url":"https://stock-news.laohu8.com/highlight/detail?id=2628454697","media":"路透中文","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628454697?lang=zh_tw&edition=fundamental","pubTime":"2026-04-20 17:16","pubTimestamp":1776676608,"startTime":"0","endTime":"0","summary":"4月20日 - ** 美国总统特朗普周六签署了一项行政命令 ，要求卫生监管机构加快对伊博格堿等迷幻药的审查，并拨出5000万美元用于研究，此后迷幻药开发商的股价在盘前上涨。** 杰富瑞指出，获得 \"突破性疗法 \"称号的迷幻药可能会获得 \"局长国家优先审查券\"，从而将食品及药物管理局的审查时间从 6-10 个月缩短到 1-2 个月。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nL4T4130IH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CMPS","DFTX","ATAI","BK4139","ENVB","GHRS","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180337716","title":"Definium Therapeutics 研發DT120口腔崩解片 針對廣泛性焦慮症、重度抑鬱症及其他嚴重腦健康疾病","url":"https://stock-news.laohu8.com/highlight/detail?id=1180337716","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180337716?lang=zh_tw&edition=fundamental","pubTime":"2026-04-19 07:43","pubTimestamp":1776555796,"startTime":"0","endTime":"0","summary":"Definium Therapeutics公司正在积极推进其核心产品DT120口腔崩解片的研发进程，该药物主要瞄准广泛性焦虑症、重度抑郁症以及其他一系列严重的脑健康疾病的治疗领域。\n这款名为DT120 ODT的创新疗法，展现了公司在精神健康与神经系统疾病治疗方面的前沿探索。其研发策略聚焦于解决当前临床未满足的重大需求，旨在为深受相关疾病困扰的患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626891167","title":"美國研究綜述-雪佛龍、Littelfuse、派克-漢尼汾","url":"https://stock-news.laohu8.com/highlight/detail?id=2626891167","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626891167?lang=zh_tw&edition=fundamental","pubTime":"2026-04-10 15:38","pubTimestamp":1775806733,"startTime":"0","endTime":"0","summary":"美国研究综述-雪佛龙、Littelfuse、派克-汉尼汾路透4月10日 - 华尔街证券分析师周五调整了对雪佛龙、Littelfuse 和派克-汉尼汾等几家美国上市公司的评级和目标价。* Whitestone REIT WSR.N：Alliance Global Partners将目标价从17美元上调至19美元(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nL4T40T0L7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2290526834.HKD","LU0054578231.USD","LU2125910179.SGD","LU1983299246.USD","AIM","ASRT","STZ","URI","LU0792757196.USD","IE00B2B36J28.USD","BK4109","MIDD","WSR","LU1861219969.SGD","OSK","LU2095319765.USD","TEX","BK4231","CE","CC","HRI","WAB","ESAB","LU2089985449.USD","LFUS","LU2089984988.USD","IE00B19Z6F94.USD","LU2238339852.HKD","LABX","ITW","ALAB","WM","LU2211814178.USD","CVX","MSGS","PH","DOW","ABBV","RSG","DE","LU2413666699.HKD","SPIR","PLNT","WLK","OLN","DFTX","LU2210149790.SGD","LU0057025933.USD","WCN","LU1854103824.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626167899","title":"美國研究綜述-雪佛龍、Littelfuse、派克-漢尼汾","url":"https://stock-news.laohu8.com/highlight/detail?id=2626167899","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626167899?lang=zh_tw&edition=fundamental","pubTime":"2026-04-10 15:38","pubTimestamp":1775806733,"startTime":"0","endTime":"0","summary":"美国研究综述-雪佛龙、Littelfuse、派克-汉尼汾路透4月10日 - 华尔街证券分析师周五调整了对雪佛龙、Littelfuse 和派克-汉尼汾等几家美国上市公司的评级和目标价。* Whitestone REIT WSR.N：Alliance Global Partners将目标价从17美元上调至19美元(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nL4S40T0L7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z4B17.USD","ESAB","LABX","LU0788109394.HKD","RSG","URI","WAB","PLNT","LFUS","LU0205193047.USD","WCN","ITW","BK4161","LU0689472784.USD","ALAB","LU1430594728.SGD","LU0114720955.EUR","ASRT","WSR","WM","IE00BKVL7J92.USD","LU2360106947.USD","LU1496350502.SGD","AIM","LU2237443895.HKD","PH","CE","DE","LU0545039389.USD","OSK","LU0612318385.USD","MIDD","WLK","LU1093756325.SGD","DOW","SGXZ23171101.USD","LU0070302665.USD","LU0175139822.USD","LU0323240290.USD","SPIR","LU0058720904.USD","ABBV","DFTX","TEX","HRI","CC","STZ","CVX","OLN","MSGS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100586830","title":"Piper Sandler 首予 Definium Therapeutics 增持評級，目標價49美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1100586830","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100586830?lang=zh_tw&edition=fundamental","pubTime":"2026-04-10 11:31","pubTimestamp":1775791902,"startTime":"0","endTime":"0","summary":"投资银行 Piper Sandler 宣布，正式开始对生物制药公司 Definium Therapeutics Inc 进行覆盖研究，并给予其“增持”评级。该机构设定了49美元的目标股价，显示出对其未来增长潜力的积极展望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":55,"code":"91000000","status":"200"}]}}